Transgene News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

03.12.20	Transgene to Present Phase 1b/2 Trial Results of TG4001 in Combination with avelumab in Advanced HPV-Positive Cancers at ESMO IO 2020 (Businesswire)
03.12.20	Transgene Appoints Hedi Ben Brahim as Chairman and Chief Executive Officer (Businesswire)
09.11.20	Transgene And BioInvent Present Data on Next Generation Oncolytic Virus BT-001 at the SITC 35th Anniversary Annual Meeting (Businesswire)
05.11.20	Transgene Reports Business Update and End Q3 2020 Financial Position (Businesswire)
05.11.20	Transgene Presents Its Individualized Immunotherapy, TG4050, at The Annual Neoantigen Based Therapies Summit (Businesswire)
27.10.20	Transgene Announces Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers (Businesswire)
19.10.20	Transgene: Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on The Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers (Businesswire)
15.10.20	Transgene and BioInvent to Present Data on Oncolytic Virus BT-001 at the SITC 35th Anniversary Annual Meeting (Businesswire)
06.10.20	Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers (Businesswire)
16.09.20	Transgene: Positive Clinical Results for TG4001 and TG6002 and Financial Visibility Secured Until 2022 (Businesswire)
09.09.20	Transgene Announces Upcoming Investor Meetings (Businesswire)
08.09.20	Positive Initial Data From a Phase 1 Trial With Transgene’s Oncolytic Virus TG6002 (Businesswire)
04.08.20	Transgene Receives $22.2 Million from the Sale of Part of its Minority Stake in Tasly BioPharmaceuticals (Businesswire)
22.07.20	Transgene Reports Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-Positive Cancers (Businesswire)
09.07.20	Transgene and Hypertrust Patient Data Care Announce Successful Go-Live of the World’s First Blockchain Solution for Clinical Trials of Personalized Healthcare (Businesswire)
22.06.20	Transgene’s and BioInvent’s BT-001 Achieves Outstanding Tumor Cure Rates in Preclinical Models (Businesswire)
22.06.20	Transgene Presents Promising New Data from its Next-Generation Immunotherapy Platforms at AACR 2020 (Businesswire)
27.05.20	Transgene: Combined General Meeting of May 27, 2020 (Businesswire)
15.05.20	Transgene and BioInvent Present Preclinical Data Demonstrating BT-001’s Powerful Activity Against Solid Tumors (Businesswire)
15.05.20	Transgene and NEC Demonstrate High Accuracy of AI-Based Neoantigen Prediction for the Design of Individualized Cancer Vaccine TG4050 (Businesswire)
06.05.20	Transgene Reports Q1 2020 Financial Position and Business Update (Businesswire)
04.05.20	Vaxxel Acquires Transgene's DuckCelt®-T17 Cell Line to Develop Industrial-scale Vaccines Against Respiratory Viruses (Businesswire)
11.03.20	Transgene: Major R&D Milestones Achieved in 2019 and Strong Clinical Activity In 2020 (Businesswire)
03.03.20	Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses (Businesswire)
20.02.20	First Patient Dosed With Transgene’s Oncolytic Virus TG6002, Administered by Intrahepatic Artery Infusion in Colorectal Cancer With Liver Metastases (Businesswire)
07.01.20	Transgene and NEC Start Two Clinical Trials with TG4050, an Individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers (Businesswire)
18.12.19	Transgene Announces Financial Calendar for 2020 (Businesswire)
12.12.19	Transgene Reports on the Combination Trial of TG4010, Chemotherapy and Nivolumab in Non-Small Cell Lung Cancer (Businesswire)
11.12.19	Transgene and BioInvent Announce Compelling Preclinical Data For BT-001 in Solid Tumors (Businesswire)
09.12.19	Transgene Announces Investor Meetings for January 2020 (Businesswire)
14.11.19	Transgene Provides Q3 2019 Business Update, with Focus on Recently Announced Efficacy Results of TG4001 (Businesswire)
22.10.19	Transgene Will Participate in the Jefferies 2019 London Healthcare Conference (Businesswire)
30.09.19	Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019 (Businesswire)
18.09.19	Transgene Confirms the Timeline of its Clinical News Flow and Presents 2019 Half-Year Results (Businesswire)
16.09.19	Transgene Receives Approval from the French Health Authority (ANSM) to Initiate Two Clinical Trials of its Lead myvac™ Individualized Immunotherapy TG4050 (Businesswire)
29.08.19	Transgene Announces Upcoming Investor Meetings (Businesswire)
07.08.19	Transgene Provides an Update after the Interim Futility Analysis of the PHOCUS Study of Pexa-Vec in Liver Cancer (Businesswire)
02.08.19	Transgene Provides Update on PHOCUS Study of Pexa-Vec in Liver Cancer Following Planned Interim Futility Analysis (Businesswire)
02.07.19	Success of Transgene’s €48.7 Million Rights Issue (Businesswire)
05.06.19	Transgene: Peer-Reviewed Publications Confirm the Potential of Transgene’s TG4001 and TG6002 (Businesswire)
27.05.19	Last Patient Enrolled in the Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC) (Businesswire)
22.05.19	Transgene: Combined General Meeting of May 22, 2019 (Businesswire)
13.05.19	Transgene: Financial Visibility Extended to Q4 2020, Including $10 Million Revenue from Collaboration with AstraZeneca to Be Received in Q2 2019 (Businesswire)
13.05.19	Transgene receives FDA IND Clearance for Lead myvac™ Individualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer (Businesswire)
09.05.19	Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 22, 2019 (Businesswire)
09.05.19	Transgene Announces Upcoming Investor Meetings (Businesswire)
02.05.19	Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement for innovative Invir.IOTM based armed oncolytic immunotherapies (Businesswire)
26.03.19	Transgene and BioInvent Extend their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors (Businesswire)
20.03.19	Transgene: A Positive 2018, Moving Ahead with a Strong Portfolio (Businesswire)
18.03.19	Transgene Secures a €20 Million Revolving Credit Facility with Natixis (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	71.40	1.91 %	K V
UBS Group	28.09	1.52 %	K V
Part Grp Hldg	1’269.00	1.20 %	K V
ABB	49.50	0.98 %	K V
Swiss Re	129.70	0.78 %	K V
Alcon	78.14	0.18 %	K V
Nestle	76.34	-0.03 %	K V
CieFinRichemont	121.40	-0.41 %	K V
Givaudan	3’854.00	-0.67 %	K V
Sonova Hldg	301.90	-0.69 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Transgene S.A.

Aktien Top/Flop

Meistgelesene Nachrichten